Aurinia Pharmaceuticals Inc AUPH
16.44
(0.16)
(0.96%)
as of 25 Sep
- Market cap
- $2.2B
- P/E
- 6.9×
Follow AUPH
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
7.10 | 6.56 | 7.35 | 19.05 |
+8 more quarters Free account |
P/S ratio |
7.09 | 6.58 | 7.57 | 5.48 | |
P/FCF ratio |
12.61 | 11.77 | 15.83 | 12.15 | |
P/Operating CF |
41.99 | 60.25 | 46.93 | 32.77 | |
P/B ratio |
3.59 | 3.46 | 3.69 | 3.98 | |
Price to Tangible BV |
3.61 | 3.48 | 3.71 | 4.02 | |
EV/Sales |
5.81 | 5.47 | 6.35 | 4.37 | |
EV/EBITDA |
11.30 | 10.93 | 13.42 | 11.66 | |
EV/Operating CF |
10.32 | 9.77 | 13.25 | 9.66 | |
EV/FCF |
10.33 | 9.79 | 13.27 | 9.68 | |
Quick Ratio |
4.85 | 4.94 | 4.69 | 5.02 | |
Current Ratio |
5.42 | 5.55 | 5.25 | 5.76 | |
Net Debt/EBITDA |
(8.88) | (7.11) | (10.47) | (8.33) | |
Debt/Assets |
5.55% | 6.65% | 6.96% | 10.56% | |
Debt/Equity |
0.07 | 0.08 | 0.09 | 0.15 | |
Asset Turnover |
0.48 | 0.49 | 0.43 | 0.49 | |
Operating CF/Net income |
1.41 | 0.95 | 0.22 | 1.41 | |
Capex/Depreciation |
0.00 | (0.01) | (0.01) | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
15.68% | 9.61% | 14.13% | 11.48% | |
Selling, General and Administrative Expense of Revenue |
28.25% | 28.35% | 37.94% | 35.64% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
3.41% | (1.11%) | 8.72% | 8.06% | |
Graham Net Nets |
0.16 | 0.17 | 0.15 | 0.19 | |
Graham Number |
15.94 | 14.77 | 14.53 | 6.02 | |
Earnings Yield |
14.08% | 15.25% | 13.61% | 5.25% | |
Free Cash Flow Yield |
7.93% | 8.49% | 6.32% | 8.23% | |
Revenue per Share |
0.64 | 0.59 | 0.57 | 0.56 | |
Operating CF per Share |
0.40 | 0.25 | 0.34 | 0.34 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.40 | 0.25 | 0.34 | 0.34 | |
Cash per Share |
3.41 | 2.86 | 2.96 | 2.67 | |
Shareholders Equity per Share |
4.73 | 4.29 | 4.33 | 2.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.73 | 4.29 | 4.33 | 2.78 | |
Free Cash Flow |
52.57 | 32.52 | 45.60 | 44.38 | |
Working Capital |
441.43 | 393.69 | 398.24 | 362.52 | |
Capital Expenditures |
0.00 | (0.04) | (0.07) | (0.06) | |
Net Current Asset Value |
363.93 | 323.87 | 321.71 | 276.98 | |
EV/EBIT |
12.86 | 12.56 | 15.71 | 14.49 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
44.96% | 44.21% | 273.35% | 42.95% | |
Price to Operating Income |
15.70 | 15.11 | 18.73 | 18.18 | |
| Other line items | |||||
Average Receivables |
40.61 | 44.76 | 39.00 | 33.61 | |
Average Payables |
2.52 | 3.44 | 4.25 | 29.49 | |
Average Inventory |
45.83 | 46.30 | 42.46 | 41.75 | |
Average Assets |
647.41 | 614.42 | 651.12 | 538.44 | |
Average Common Equity |
475.08 | 458.91 | 479.40 | 376.89 |
Columns are period end dates